Illumina (ILMN) Valuation Check After DRAGEN v4.5 Launch And Major Pediatric Genomics Partnership

Simply Wall St.04-18

Illumina (ILMN) is back in focus after the company rolled out DRAGEN v4.5, a major software update for genomic analysis, alongside a large pediatric data partnership that is drawing fresh attention to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628732033?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-04-18 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628732033","market":"us","top_or_hot":-1,"title":"Illumina (ILMN) Valuation Check After DRAGEN v4.5 Launch And Major Pediatric Genomics Partnership","media":"Simply Wall St.","content":"<div>\n<p>Illumina (ILMN) is back in focus after the company rolled out DRAGEN v4.5, a major software update for genomic analysis, alongside a large pediatric data partnership that is drawing fresh attention to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-dragen-v45-launch-and-ma\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina (ILMN) Valuation Check After DRAGEN v4.5 Launch And Major Pediatric Genomics Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina (ILMN) Valuation Check After DRAGEN v4.5 Launch And Major Pediatric Genomics Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-18 17:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-dragen-v45-launch-and-ma><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Illumina (ILMN) is back in focus after the company rolled out DRAGEN v4.5, a major software update for genomic analysis, alongside a large pediatric data partnership that is drawing fresh attention to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-dragen-v45-launch-and-ma\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-dragen-v45-launch-and-ma","article_id":"2628732033","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-valuation-check-after-dragen-v45-launch-and-ma","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628732033","pubTimestamp":1776503206,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Illumina (ILMN) is back in focus after the company rolled out DRAGEN v4.5, a major software update for genomic analysis, alongside a large pediatric data partnership that is drawing fresh attention to its core sequencing ecosystem.\nSee our latest analysis for Illumina.\nThe latest DRAGEN v4.5 launch and the large pediatric data partnership arrive as Illumina’s share price trades at US$134.50, with a 7 day share price return of 11.22% and a 1 year total shareholder return of 88.90%. However, 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","BK4121":"生命科学工具和服务","BK4548":"巴美列捷福持仓"},"translate_title":"DRAGEN v4.5发布和主要儿科基因组学合作伙伴关系后的Illumina(ILMN)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5},"content_text":"Illumina (ILMN) is back in focus after the company rolled out DRAGEN v4.5, a major software update for genomic analysis, alongside a large pediatric data partnership that is drawing fresh attention to its core sequencing ecosystem. See our latest analysis for Illumina. The latest DRAGEN v4.5 launch and the large pediatric data partnership arrive as Illumina’s share price trades at US$134.50, with a 7 day share price return of 11.22% and a 1 year total shareholder return of 88.90%. However, 3 and 5 year total shareholder returns remain negative and indicate longer term holders have seen weaker outcomes despite the recent pickup in momentum. If genomic tools and healthcare AI are on your radar, this may be a useful moment to broaden your watchlist with 35 healthcare AI stocks With Illumina trading near its analyst price target and showing mixed long term returns, the key question for you is simple: is the recent software and data momentum a genuine mispricing opportunity, or are markets already accounting for future growth? AdvertisementMost Popular Narrative: 1% Undervalued The most followed narrative pegs Illumina’s fair value at $136.11, just above the $134.50 last close. This frames the current rally as almost perfectly in line with those expectations.  Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility. Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.  Read the complete narrative. Want to see what is baked into that near perfect match between price and fair value? The narrative leans heavily on steady top line expansion, firmer margins and a long term earnings profile that depends on how far clinical genomics goes. The tension lies in how much growth and profitability the model assumes before the discount rate brings everything back to today. Result: Fair Value of $136.11 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points, including softer research funding and ongoing regulatory uncertainty in China. These factors could challenge revenue assumptions and the current fair value story. Find out about the key risks to this Illumina narrative. Next Steps Seeing both risks and rewards in this story so far? Move quickly, review the full data set yourself, and weigh the 3 key rewards and 1 important warning sign Looking for more investment ideas? If you stop with one stock idea, you risk missing opportunities that better match your goals, so take a few minutes to scan wider and pressure test your watchlist.  Target stronger balance sheets by checking out the solid balance sheet and fundamentals stocks screener (42 results) that could handle tougher conditions better than most. Hunt for mispriced quality through the 59 high quality undervalued stocks that filters for businesses with sturdy fundamentals and room for potential upside. Spot future standouts early with the screener containing 23 high quality undiscovered gems before they attract broader attention and crowding.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628732033","isCrawlerRequest":true}